Bulent Aydogan to Combined Modality Therapy
This is a "connection" page, showing publications Bulent Aydogan has written about Combined Modality Therapy.
Connection Strength
0.140
-
Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1504-10.
Score: 0.062
-
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.
Score: 0.029
-
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 01; 79(3):800-7.
Score: 0.017
-
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009 Nov; 93(2):298-301.
Score: 0.017
-
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7.
Score: 0.015